Development status: Approved, off-patent

Gram-positive activity

Gram-negative activity

Propensity to select resistant bacteria

Combination therapy

Mechanism of Action/Target pathogen: Inhibits bacterial DNA-dependent RNA polymerase, thus inhibiting bacterial RNA synthesis

Additional information: Semisynthetic, derived from rifamycin. Used for the treatment of tuberculosis and MAC infection in combination, also active against Acinetobacter baumannii (BV100, Phase 1 as of 2022)